Play games and win money

• They characterized the temporal dynamics of transcript abundance in subjects vaccinated with rDEN3delta30/31 (TetraVax-DV live vaccine candidate Den3 component developed by NIAID).
• Of Note:
• During early transcriptional response there is an interferon-associated transcript expression pattern that peaked in most subjects between day 6 and day 12 post-immunization and this correlated with the titer of neutralizing antibodies (PRNT60) measured at day 42.

"Interferons are a class of cytokines first identified in 1957 as having a protective effect against viral infection [1]. Interferons can be divided into three groups; type I (IFN?/?/?/?/?) that engage the IFNAR1/2 receptor, type II (IFN?, the sole member) that signal through the IFNGR1/2 receptor [2], and type III (IFN?) that utilize IFN-?R1 and IL-10R2 receptors [3], [4]. 

The type I interferons, IFN? (of which there are 13 subtypes), IFN? and IFN? are secreted by most cell types in response to viral infection [5]. Mice lacking intact interferon receptors are highly susceptible to viral infection [6]. Type I IFN stimulation induces a number of different systems involved in the activation of the immune response, cell growth and the control of apoptosis, in addition to the PKR (dsRNA-dependent protein kinase), 2-5A synthetase and Mx antiviral systems [7], [8]. Type I interferon subtypes have also been reported to have distinct activities [9], [10]; these IFN subtype-specific effects are influenced by factors such as receptor binding efficiencies [11], constitutive levels of IFN expression [12], and the specific viral-target cell combination [13]. By contrast type II interferon (IFN?), secreted by activated NK cells and T lymphocytes, has been implicated primarily in the activation of macrophages and has been demonstrated to be important for the protection of the host against intracellular pathogens such as Leishmania, Toxoplasma and Mycobacterium species [14]. Mutations in the IFN? receptor have been associated with increased susceptibility to mycobacterial infection [15]. Interferons are involved in a wide range of clinically important phenomena, ranging from activation of immune responses to infection [14] to cancer suppression [16] to depression [17]. Recombinant interferon therapy has been approved for a spectrum of conditions such as hepatitis B and C infections, Kaposis sarcoma, multiple sclerosis and chronic granulomatous disease [5]."